Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company is headquartered in New York, New York.

Neurogene Inc.

Neurogene Inc. ( ($NGNE) ) has released its Q3 earnings. Here is a breakdown of the information Neurogene Inc. presented to its investors. Neurogen...

Market Cap	$305.77M	P/E Ratio	N/A
52W High	$37.27	52W Low	$6.88
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	0.9%	52W Position	46.2%
Overall Score	35	Value Score	60
Quality Score	28	Technical Score	18

EPS Current Est	$-4.37	EPS Next Est	$-5.19
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NGNE	$20.92	-1.60%	144.44K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NGNE	$20.92	-1.6%	144.44K
3
4
5
6

NGNE

NGNE

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Neurogene Inc. Data in Excel

Get Neurogene Inc. Data in Excel